Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates

Clinical Pharmacokinetics

Volumn 46, Issue 1, 2007, Pages 59-74

  Micallef, Sandrine ^a   Amzal, Billy ^b   Bach, Véronique ^c   Chardon, Karen ^c   Tourneux, Pierre ^d   Bois, Frédéric Y ^a  

^a INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d Hospital of Amiens   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE;

ALGORITHM; ARTICLE; BAYES THEOREM; BODY MASS; CHILD GROWTH; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; HUMAN; MEDICAL DECISION MAKING; NEWBORN; POPULATION STRUCTURE; PREDICTION; PREMATURITY; PRIORITY JOURNAL; STOCHASTIC MODEL;

BAYES THEOREM; CAFFEINE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE;

EID: 33846159868     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746010-00003     Document Type: Article

References (50)

1. Daily WJ, Klaus M, Meyer HB. Apnea in premature infants: monitoring, incidence, heart rate changes, and an effect of environmental temperature. Pediatrics 1969; 43 (4): 510-8
2. Aranda JV, Turmen T, Davis J, et al. Effect of caffeine on control of breathing in infantile apnea. J Pediatr 1983; 103 (6): 975-8
3. Aranda JV, Gorman W, Bergsteinsson H, et al. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1977; 90 (3): 467-72
4. Aranda JV, Grondin D, Sasyniuk BI. Pharmacologic considerations in the therapy of neonatal apnea. Pediatr Clin North Am 1981; 28 (1): 113-33
5. Zanardo V, Dani C, Trevisanuto D, et al. Methylxanthines increase renal calcium excretion in preterm infants. Biol Neonate 1995; 68 (3): 169-74
6. Gillot I, Gouyon JB, Guignard JP. Renal effects of caffeine in preterm infants. Biol Neonate 1990; 58: 133-6
7. D'Urzo AD, Jhirad R, Jenne H, et al. Effect of caffeine on ventilatory responses to hypercapnia, hypoxia, and exercice in humans. J Appl Physiol 1990; 68 (1): 322-8
8. Aranda JV, Clozel M. Pharmacologic effects of caffeine and theophylline in the premature infant. Dev Pharmacol Ther 1982; 4 Suppl.: 165-72
9. Karacan I, Thornby JI, Anch M, et al. Dose-related sleep disturbances induced by coffee and caffeine. Clin Pharmacol Ther 1976; 20 (6): 682-9
10. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 2000; (2): CD000140
11. Bhatt-Mehta V, Schumacher RE. Treatment of apnea of prematurity. Paediatr Drugs 2003; 5 (3): 195-210
12. Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit 1996; 18 (3): 245-53
13. Lee TC, Charles B, Steer P, et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther 1997; 61 (6): 628-40
14. Falcao AC, Fernandez de Gatta MM, Delgado Iribarnegaray MF, et al. Population pharmacokinetics of caffeine in premature neonates. Eur J Clin Pharmacol 1997; 52 (3): 211-7
15. Box GEP, Tiao G. Bayesian inference in statistical analysis. New York: John Wiley and Sons, 1973
16. Gelman A, Carlin JB, Stern HS, et al. Bayesian data analysis. London: Chapman & Hall, 1995
17. Bernardo JM, Smith AFM. Bayesian theory. New York: Wiley, 1994
18. Amzal B, Bois FY, Parent E, et al. Bayesian optimal design via interacting particle systems. J Am Stat Assoc 2006; 101 (474): 773-85
19. Warszawski D, Gorodischer R. Tissue distribution of caffeine in premature infants and in newborn and adult dogs. Pediatr Pharmacol (New York) 1981; 1 (4): 341-6
20. International Commission on Radiological Protection (ICRP). Basic anatomical and physiological data for use in radiological protection: reference values. Stockholm: Pergamon, 2002
21. Pons G, Carrier O, Richard M-O, et al. Developmental changes of caffeine elimination in infancy. Dev Pharmacol Ther 1988; 11: 258-64
22. Carrier O, Pons G, Rey E, et al. Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther 1988; 44 (2): 145-51
23. Bourgoin H, Paintaud G, Buchler M, et al. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol 2005; 59 (1): 18-27
24. Sandstrom M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001; 28 (7): 657-64
25. Taright N, Mentre F, Mallet A, et al. Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach. Ther Drug Monit 1994; 16 (3): 258-69
26. Arnaud M. Metabolism of caffeine and other components of coffee. In: Garattini S, editor. Caffeine, coffee and health. New York: Raven Press, 1993: 43-93
27. Aranda JV, Collinge JM, Zinman R, et al. Maturation of caffeine elimination in infancy. Arch Dis Child 1979; 54 (12): 946-9
28. Le Guennec JC, Billon B, Pare C. Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. Pediatrics 1985; 76 (5): 834-40
29. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8 (3): 195-222
30. Racine-Poon A, Smith AF. Population models. In: Berry DA, editor. Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker Inc, 1990: 139-162
31. Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. J Am Stat Assoc 2005; 100 (470): 680-700
32. Kadane JB, Wolfson LJ. Experiences in elicitation. J R Stat Series D (The Statistician) 1998; 47 (1): 3-19
33. Chen MH, Ibrahim JG, Shao QM, et al. Prior elicitation model selection and estimation in generalized linear mixed models. J Stat Plan Inference 2003; 111 (1-2): 57-76
34. Arnaud M, Weitzholtz H, Voegelin M, Bircher J, Presig Assessment of the cytochrome P-448 dependent liver enzyme system by caffeine breath test. In: Sato R, editor. Microsomes drug oxydation and drug toxicity. New York: Wiley Interscience, 1982: 443-4
35. Stone M. Cross-validation choice and assessment of statistical predictions. J R Stat Soc B 1974; 36: 111-47
36. Gelfand AE, Dey DK, Chang H. Model determination using predictive distributions with implementation via sampling-based methods. In: Bernardo JM, Berger JO, Dawid AP, et editors. Bayesian statistics 4. Oxford: Oxford University Press, 1992: 147-67
37. Robert C. Méthodes de Monte Carlo par châines de Markov. Paris: Economica, 1996
38. Gilks WR, Richardson S, Spiegelhalter DJ. Markov chain Monte Carlo in practice. London: Chapman & Hall, 1996
39. Bois FY, Maszle D. MCSim: a simulation program. Journal Statistical Software 1997; 2 (9) [online]. Available from URL: http://toxi.ineris.fr/ activites/toxicologie_quantitative/mcsim/mcsim.php [Accessed 2006 Nov 27]
40. Chopin N. A sequential particle filter method for static models. Biometrika 2002; 89: 539-52
41. Tierney L, Mira A. Some adaptive Monte Carlo methods Bayesian inference. Stat Med 1999; 18: 2507-15
42. Doucet A, Godsill S, Andrieu C. On sequential Monte Carlo sampling methods for Bayesian filtering. Statistics and Computing 2000; 10 (3): 197-208
43. Doucet A, De Freias J, Gordon N. Sequential Monte Carlo methods in practice. New York: Springer-Verlag, 2001
44. Ridgeway G, Madigan D. A sequential Monte Carlo method for Bayesian analysis of massive datasets. Data Mining and Knowledge Discovery 2003; 7 (3): 301-19
45. Bayard DS, Jelliffe RW. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn 2004; 31 (1): 75-107
46. Geweke J. Bayesian inference in econometric models using Monte Carlo integration. Econometrica 1989; 24: 1317-99
47. Rubin DB. Using the SIR algorithm to simulate posterior distributions. In: Bernardo JM, De Groot MH, Lindley DV, et al., editors. Bayesian statistics 3. Oxford: Oxford University Press, 1988: 395-402
48. Tierney L. Markov chains for exploring posterior distributions. Ann Stat 1994; 22 (4): 1701-62
49. Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/ pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22 (3): 354-65
50. Wakefield J, Walker S. Bayesian nonparametric population models: formulation and comparison with likelihood approaches. J Pharmacokinet Biopharm 1997; 25 (2): 235-53